Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

Some online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...